Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Curis | CRIS | Mar 31, 2025 | 2.10 | -9.48 |
CURRENC Group | CURR | Mar 31, 2025 | 1.51 | +3.42 |
Curtiss-Wright | CW | Mar 31, 2025 | 317.27 | +0.15 |
Cushing Mlp & Infrastructure Total Return Fund | SRV | Mar 31, 2025 | 43.95 | -0.27 |
Cushman & Wakefield | CWK | Mar 31, 2025 | 10.22 | +0.29 |
Custom Truck One Source | CTOS | Mar 31, 2025 | 4.22 | -5.17 |
Customers Bancorp | CUBI | Mar 31, 2025 | 50.20 | +0.12 |
Customers Bancorp E Pref | CUBI-E | Mar 31, 2025 | 25.72 | +0.04 |
Customers Bancorp F Pref | CUBI-F | Mar 31, 2025 | 25.40 | +0.39 |
Cutera | CUTR | Mar 31, 2025 | 0.11 | 0.00 |
CVB Financial | CVBF | Mar 31, 2025 | 18.46 | 0.00 |
CVD Equipment | CVV | Mar 31, 2025 | 3.07 | +0.99 |
CVR Energy | CVI | Mar 31, 2025 | 19.40 | -2.12 |
Cvr Partners LP Unit | UAN | Mar 31, 2025 | 75.17 | +0.43 |
CVRx | CVRX | Mar 31, 2025 | 12.23 | -2.08 |
CVS Health | CVS | Mar 31, 2025 | 67.75 | +0.91 |
CXApp A | CXAI | Mar 31, 2025 | 0.90 | +9.61 |
CyberArk Software | CYBR | Mar 31, 2025 | 338.00 | +0.67 |
Cybin | CYBN | Mar 31, 2025 | 6.34 | -5.65 |
Cyclacel Pharmaceuticals | CYCC | Mar 31, 2025 | 0.28 | -6.62 |
Cyclacel Pharmaceuticals Pref | CYCCP | Mar 31, 2025 | 4.68 | -13.97 |
Cyclerion Therapeutics | CYCN | Mar 31, 2025 | 2.50 | -2.72 |
Cyclo Therapeutics | CYTH | Mar 31, 2025 | 0.72 | 0.00 |
Cycurion | CYCU | Mar 31, 2025 | 0.50 | 0.00 |
Cyngn | CYN | Mar 31, 2025 | 4.53 | +0.44 |
Cytek Biosciences | CTKB | Mar 31, 2025 | 4.01 | +0.25 |
Cytokinetics | CYTK | Mar 31, 2025 | 40.19 | -6.95 |
Cytomed Therapeutics | GDTC | Mar 31, 2025 | 2.18 | -3.09 |
CytomX Therapeutics | CTMX | Mar 31, 2025 | 0.64 | +1.21 |
Cytosorbents | CTSO | Mar 31, 2025 | 1.00 | 0.00 |
|
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.